There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Global Blood Therapeutics (NASDAQ:GBT) and Alder Biopharmaceuticals (NASDAQ:ALDR) with bullish sentiments.
Global Blood Therapeutics (GBT)
Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Global Blood Therapeutics yesterday and set a price target of $96. The company’s shares closed yesterday at $46.85.
According to TipRanks.com, Piros has currently no stars on a ranking scale of 0-5 stars, with an average return of -8.3% and a 39.1% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Bellicum Pharmaceuticals.
Global Blood Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $84.56, an 80.5% upside from current levels. In a report issued on July 25, William Blair also assigned a Buy rating to the stock.
.
See today’s analyst top recommended stocks >>
Alder Biopharmaceuticals (ALDR)
Mizuho Securities analyst Difei Yang maintained a Buy rating on Alder Biopharmaceuticals today and set a price target of $29. The company’s shares closed yesterday at $19.40, close to its 52-week high of $20.
According to TipRanks.com, Yang is a top 100 analyst with an average return of 22.8% and a 54.8% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Audentes Therapeutics, and Revance Therapeutics.
Alder Biopharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $25.33, implying a 30.6% upside from current levels. In a report issued on August 6, Piper Jaffray also initiated coverage with a Buy rating on the stock with a $28 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
